US › Healthcare

Cadrenal Therapeutics, Inc. Common Stock (CVKD)

US · Healthcare · Biotechnology

$2.03+3.57%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-2.5M
Profit YoY
+35.1%
EPS
$-1.04
EPS estimate
$-1.57

EPS came in at -1.04 against a street estimate of -1.57 — a beat of 33.8%.

Key statistics

Market cap
$6.2M
Forward P/E
0.0
P/B
3.47
Book value
$0.72
EPS (TTM)
$-5.59
52-week high
$14.64
52-week low
$1.86
50-day MA
$3.33
200-day MA
$6.87
Beta
1.75

Analyst view

Analysts rate Cadrenal Therapeutics, Inc. Common Stock a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $16.67.

Shareholding

Insiders
13.73%
Institutions
3.07%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC1.46%
Geode Capital Management, LLC0.70%
Vanguard Fiduciary Trust Co0.27%
JPMorgan Chase & Co0.24%
BlackRock Inc0.18%
Cygnus Capital Advisors, LLC0.05%
Coconut Grove Bank0.03%
Tower Research Capital LLC0.01%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Cadrenal Therapeutics, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.